ES2987442T3 - Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer - Google Patents

Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer Download PDF

Info

Publication number
ES2987442T3
ES2987442T3 ES16722384T ES16722384T ES2987442T3 ES 2987442 T3 ES2987442 T3 ES 2987442T3 ES 16722384 T ES16722384 T ES 16722384T ES 16722384 T ES16722384 T ES 16722384T ES 2987442 T3 ES2987442 T3 ES 2987442T3
Authority
ES
Spain
Prior art keywords
adenovirus
epitope
cancer
tumor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16722384T
Other languages
English (en)
Spanish (es)
Inventor
Ramon Alemany
Raul Gil
Miriam Bazan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theriva Biologics S L
Theriva Biologics SL
Original Assignee
Theriva Biologics S L
Theriva Biologics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theriva Biologics S L, Theriva Biologics SL filed Critical Theriva Biologics S L
Application granted granted Critical
Publication of ES2987442T3 publication Critical patent/ES2987442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES16722384T 2015-05-04 2016-05-04 Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer Active ES2987442T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156748P 2015-05-04 2015-05-04
PCT/IB2016/052554 WO2016178167A1 (en) 2015-05-04 2016-05-04 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment

Publications (1)

Publication Number Publication Date
ES2987442T3 true ES2987442T3 (es) 2024-11-14

Family

ID=55967340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16722384T Active ES2987442T3 (es) 2015-05-04 2016-05-04 Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer

Country Status (7)

Country Link
US (1) US11000560B2 (enExample)
EP (1) EP3292142B1 (enExample)
JP (1) JP6740340B2 (enExample)
CN (1) CN107849111B (enExample)
AU (1) AU2016257196B2 (enExample)
ES (1) ES2987442T3 (enExample)
WO (1) WO2016178167A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
EP3833765B1 (en) * 2017-08-09 2026-01-14 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
CN109576231B (zh) 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
DK3762004T3 (da) * 2018-03-05 2023-11-27 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor
GB201804468D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
US12295976B2 (en) 2018-03-28 2025-05-13 Epicentrx, Inc. Personalized cancer vaccines
CN110856751B (zh) 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
CN110669740B (zh) * 2019-07-16 2021-10-08 伍泽堂 溶瘤病毒及其应用和治疗癌症的药物
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
CN114292830B (zh) * 2021-12-31 2024-05-03 复旦大学 蛋白SaCas9的抗原表位及其在基因编辑中的应用
EP4680727A2 (en) * 2023-03-17 2026-01-21 Walking Fish Therapeutics, Inc. Methods for in vivo editing of b cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
SI2163260T1 (sl) * 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080292592A1 (en) * 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2007015540A1 (ja) * 2005-08-03 2007-02-08 Medical And Biological Laboratories Co., Ltd. 細胞傷害性ｔ細胞エピトープペプチド及びその用途
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
JP2012513209A (ja) * 2008-12-22 2012-06-14 オンコス セラピュティックス オサケ ユキチュア 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20120107270A1 (en) * 2009-06-30 2012-05-03 Manuela Kaspar Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
CN103237889B (zh) * 2010-08-16 2017-04-05 萨克生物研究学院 腺病毒组装方法
EP2619224A1 (en) 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP2643347B1 (en) * 2010-11-25 2017-12-27 Imnate Sarl Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells
US11155599B2 (en) * 2012-02-02 2021-10-26 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof

Also Published As

Publication number Publication date
EP3292142B1 (en) 2024-03-20
CN107849111A (zh) 2018-03-27
JP6740340B2 (ja) 2020-08-12
US11000560B2 (en) 2021-05-11
AU2016257196B2 (en) 2021-11-25
JP2018519847A (ja) 2018-07-26
CA2985029A1 (en) 2016-11-10
WO2016178167A1 (en) 2016-11-10
EP3292142A1 (en) 2018-03-14
US20180153946A1 (en) 2018-06-07
CN107849111B (zh) 2022-02-22
AU2016257196A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
US11000560B2 (en) Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
ES3041285T3 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
JP7468958B2 (ja) 腫瘍溶解性ウイルスワクチン及びそれと免疫細胞の併用による腫瘍治療薬物
ES2883354T3 (es) Vector adenoviral
ES2358204T3 (es) Adenovirus quiméricos para uso en el tratamiento del cáncer.
AU2016274655B2 (en) HPV vaccines
ES2741147T3 (es) Composición de vacuna
JP6230527B2 (ja) サルアデノウイルス及び雑種アデノウイルスベクター
Asad et al. Viral gene therapy for breast cancer: progress and challenges
CN109312366B (zh) 用于肿瘤溶瘤治疗的vsv/ndv杂合病毒
US10617729B2 (en) Multitargeting onocolytic adenovirus, methods of use, and methods of making
ES2795833T3 (es) Composiciones para la vacunación contra el virus del Ebola
ES2367227T3 (es) Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer.
KR102686295B1 (ko) 아데노바이러스 및 아데노바이러스의 사용 방법
US20190151437A1 (en) Combination prime: boost therapy
CN108025088B (zh) 溶瘤性hsv1载体及其使用方法
CN116171168A (zh) 通过靶向抗原表达增强免疫应答
ES2963232T3 (es) Promotor derivado de poxvirus y vector que lo comprende
US20160002667A1 (en) Pseudomonas exotoxins for cancer treatment
ES2700749T3 (es) Uso de un virus del sarampión infeccioso genéticamente modificado con propiedades proapoptóticas potenciadas (virus MV-deltaC) en la terapia del cáncer
CA2985029C (en) Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
JP2026502453A (ja) がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ）
US20220184202A1 (en) A recombinant htlv-1 vaccine
ES3018628T3 (es) Adenovirus oncolíticos no humanos y usos de los mismos
Rodríguez García Enhancing the antitumor activity of oncolytic adenoviruses by combining tumor targeting with hyaluronidase expression or by increasing the immunogenicity of exogenous epitopes